Key Developments

In March 2024, Aquestive Therapeutics, Inc., Pharmaceutical company announced successful results from a phase 3 study of their sublingual epinephrine product, Anaphylm Sublingual Film, which met all primary and secondary pharmacokinetic endpoints for treating serious allergic reactions like anaphylaxis. These findings were highlighted during a recent USFDA Type C meeting.
In December 2023, Nasus Pharma Ltd, clinical-stage biopharmaceutical company completed an additional Phase II clinical trial affirming the efficacy and safety of its FMXIN002 Intranasal Epinephrine product.
In March 2023, Daiichi Sankyo, Inc., global healthcare company operating through its subsidiary American Regent, Inc., launched a sulfite-free Epinephrine Injection, USP, designed for emergency treatment of type I allergic reactions.
In October 2022, ARS Pharmaceuticals, Biotechnology company announced FDA acceptance of its new drug application for Neffy, an epinephrine nasal spray.
In November 2020, Upjohn, a division of Pfizer Inc., and Mylan N.V. joined forces to create Viatris Inc., a global pharmaceutical company focused on developing products in areas such as cardiovascular diseases, central nervous system disorders, anesthesia, and infectious diseases worldwide.